140,676 results match your criteria acute leukemia


Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.

Cell Stem Cell 2021 Sep 9. Epub 2021 Sep 9.

University of Minnesota, Department of Medicine, Minneapolis, MN 55455, USA. Electronic address:

Select subsets of immune effector cells have the greatest propensity to mediate antitumor responses. However, procuring these subsets is challenging, and cell-based immunotherapy is hampered by limited effector-cell persistence and lack of on-demand availability. To address these limitations, we generated a triple-gene-edited induced pluripotent stem cell (iPSC). Read More

View Article and Full-Text PDF
September 2021

Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience.

Blood Adv 2021 Sep 15. Epub 2021 Sep 15.

University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States.

Acute lymphoblastic leukemia (ALL) with t(4;11)(q21;q23) - KMT2A-AFF1 is associated with a poor prognosis. The impact of KMT2A rearrangements other than t(4;11) is uncertain and the benefit of allogeneic stem cell transplant (HSCT) is unclear. We reviewed adult patients with ALL treated at our institution from 1984 to 2019 and identified 50/1102 (5%) with KMT2A rearrangement: 42 (84%) with t(4;11)/KMT2A-AFF1 and 8 (16%) with other gene partners. Read More

View Article and Full-Text PDF
September 2021

Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk-stratification, and treatment.

Blood Adv 2021 Sep 15. Epub 2021 Sep 15.

Benioff Children's Hospital, University of California, San Francisco, San Francisco, California, United States.

Juvenile myelomonocytic leukemia is an overlapping myeloproliferative and myelodysplastic disorder of early childhood. It is associated with a spectrum of diverse outcomes ranging from spontaneous resolution in rare patients to transformation to acute myeloid leukemia in others that is generally fatal. This unpredictable clinical course, along with initially descriptive diagnostic criteria, led to decades of productive international research. Read More

View Article and Full-Text PDF
September 2021

In-depth time-dependent analysis of the benefit of Allo-HSCT for elderly patients with CR1 AML: a FILO study.

Blood Adv 2021 Sep 15. Epub 2021 Sep 15.

IUCT Oncopole, TOULOUSE, France.

The benefit of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) for acute myeloid leukemia (AML) patients over 60 years remains a matter of debate, notably when performed in first complete remission (CR1). In order to clarify this issue, the French Innovative Leukemia Organization (FILO) performed a 10-year real-world time-dependent analysis. The study enrolled patients between 60 and 70 years of age with AML in CR1 after intensive chemotherapy with intermediate (IR) or unfavorable (UR) risk according to the European LeukemiaNet (ELN)-2010. Read More

View Article and Full-Text PDF
September 2021

Portable Medical Orders and End of Life Measures in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Blood Adv 2021 Sep 15. Epub 2021 Sep 15.

University of Rochester Medical Center, Rochester, New York, United States.

Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) experience high rates of hospitalization, intensive care unit (ICU) admissions, and in-hospital deaths at end of life (EOL). Early goals-of-care (GOC) discussions might reduce intensity of care at EOL. Portable Medical Order (POLST) forms, known as Medical Orders for Life Sustaining Treatment (MOLST) forms in New York State, allow patients to translate GOC discussions into specific medical orders that communicate their wishes during a medical emergency. Read More

View Article and Full-Text PDF
September 2021

Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.

Int J Hematol 2021 Sep 14. Epub 2021 Sep 14.

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.

The efficacy of pharmacokinetically (PK) guided, once-daily administration of busulfan (BU) was evaluated in elderly patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Twenty-one patients (median age 61) received 30 mg/m fludarabine for 6 days and BU for 4 days, starting from 3.2 mg/m and subsequently adjusted to the target area under the curve (AUC) of 6000 µmol-min/L. Read More

View Article and Full-Text PDF
September 2021

Indications and diagnostic value of bone marrow examination in HIV-positive individuals: A 3-year review at Tygerberg Hospital.

S Afr J Infect Dis 2021 23;36(1):273. Epub 2021 Aug 23.

Department of Haematological Pathology, Stellenbosch University, Cape Town, South Africa.

Background: Bone marrow examination is a useful diagnostic tool in human immunodeficiency virus (HIV)-positive patients presenting with cytopenias and fever. However, its role in the afebrile and asymptomatic patient presenting with an isolated cytopenia is not well established. This study was conducted to determine the indications for bone marrow examination and its diagnostic yield, in HIV-positive patients at Tygerberg Hospital. Read More

View Article and Full-Text PDF

The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme.

Cancer Gene Ther 2021 Sep 14. Epub 2021 Sep 14.

Division of Clinical Studies, Institute of Cancer Research, London, UK.

Deregulated polyamine biosynthesis is emerging as a common feature of neuroblastoma and drugs targeting this metabolic pathway such as DFMO are in clinical and preclinical development. The polyamine analog verlindamycin inhibits the polyamine biosynthesis pathway enzymes SMOX and PAOX, as well as the histone demethylase LSD1. Based on our previous research in acute myeloid leukemia (AML), we reasoned verlindamycin may also unblock neuroblastoma differentiation when combined with all-trans-retinoic acid (ATRA). Read More

View Article and Full-Text PDF
September 2021

Genomic and transcriptomic analyses reveal a tandem amplification unit of 11 genes and mutations in mismatch repair genes in methotrexate-resistant HT-29 cells.

Exp Mol Med 2021 Sep 14. Epub 2021 Sep 14.

Asian Genome Institute, Seoul National University Bundang Hospital, Seongnamsi, 13605, Korea.

DHFR gene amplification is commonly present in methotrexate (MTX)-resistant colon cancer cells and acute lymphoblastic leukemia. In this study, we proposed an integrative framework to characterize the amplified region by using a combination of single-molecule real-time sequencing, next-generation optical mapping, and chromosome conformation capture (Hi-C). We identified an amplification unit spanning 11 genes, from the DHFR gene to the ATP6AP1L gene position, with high adjusted interaction frequencies on chromosome 5 (~2. Read More

View Article and Full-Text PDF
September 2021

KCTD15 deregulation is associated with alterations of the NF-κB signaling in both pathological and physiological model systems.

Sci Rep 2021 Sep 14;11(1):18237. Epub 2021 Sep 14.

IRCCS SDN, Via E. Gianturco 113, 80143, Naples, Italy.

Like other KCTD proteins, KCTD15 is involved in important albeit distinct biological processes as cancer, neural crest formation, and obesity. Here, we characterized the role of KCTD15 in different physiological/pathological states to gain insights into its diversified function(s). The silencing of KCTD15 in MLL-rearranged leukemia models induced attenuation of the NF-κB pathway associated with a downregulation of pIKK-β and pIKB-α. Read More

View Article and Full-Text PDF
September 2021

Therapeutic targeting of the inflammasome in myeloid malignancies.

Blood Cancer J 2021 Sep 14;11(9):152. Epub 2021 Sep 14.

Division of Hemato-Oncology, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA.

Even though genetic perturbations and mutations are important for the development of myeloid malignancies, the effects of an inflammatory microenvironment are a critical modulator of carcinogenesis. Activation of the innate immune system through various ligands and signaling pathways is an important driver of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The DAMPs, or alarmins, which activate the inflammasome pathway via the TLR4/NLR signaling cascade causes the lytic cell death of hematopoietic stem and progenitor cells (HSPCs), ineffective hematopoiesis, and β-catenin-induced proliferation of cancer cells, leading to the development of MDS/AML phenotype. Read More

View Article and Full-Text PDF
September 2021

Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia.

Signal Transduct Target Ther 2021 Sep 15;6(1):334. Epub 2021 Sep 15.

Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, People's Republic of China.

View Article and Full-Text PDF
September 2021

Diagnosis of Sweet's syndrome in otolaryngology.

BMJ Case Rep 2021 Sep 14;14(9). Epub 2021 Sep 14.

Otorhinolaryngology and Head & Neck Surgery, UMC Utrecht, Utrecht, The Netherlands.

Sweet's syndrome (acute febrile neutrophilic dermatosis) consists of acute onset of painful cutaneous erythematous lesions, mostly found in the upper extremities followed by the head and neck region, particularly in patients with underlying malignancies. We describe the case of a woman in her mid-30s, who was treated for acute myeloid leukaemia and presented with a severe painful and progressive erythematous lesion of the retroauricular skin. Clinical features, laboratory tests, blood cultures and histological biopsy yielded a diagnosis of Sweet's syndrome. Read More

View Article and Full-Text PDF
September 2021

Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia.

J Geriatr Oncol 2021 Sep 11. Epub 2021 Sep 11.

Janssen Global Services, LLC, Raritan, NJ, USA.

Introduction: Patient-reported outcomes (PROs) predict overall survival (OS) in many cancer types, but there is little evidence of their prognostic value in older patients with acute myeloid leukemia (AML). We examined whether the Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) predicted OS beyond established prognostic factors among these patients.

Materials And Methods: Data were from AML2002 (n = 309), a randomized phase 2/3 study comparing decitabine plus talacotuzumab versus decitabine alone in older AML patients ineligible for intensive chemotherapy. Read More

View Article and Full-Text PDF
September 2021

Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.

Blood Adv 2021 Sep 14. Epub 2021 Sep 14.

Stanford University, Stanford, California, United States.

Bleeding and thrombotic events are an emerging toxicity associated with chimeric antigen receptor (CAR) therapies. To determine their incidence, we retrospectively analyzed consecutive adult patients (n=127) with large B-cell lymphoma (LBCL) or B-cell acute lymphoblastic leukemia (B-ALL) treated between 2017-2020 with axicabtagene ciloleucel (axi-cel) (N=89) or a bispecific CD19/CD22 CAR (N=38). 12 (9. Read More

View Article and Full-Text PDF
September 2021

Childhood cancer hospital resource utilization and costs in Egypt, 2013-2017; patterns, trends, and associated factors for 8886 patients from Children's Cancer Hospital, Egypt.

Pediatr Blood Cancer 2021 Sep 14:e29347. Epub 2021 Sep 14.

Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Introduction: There is a lack ofevidence about resource use and costs of childhood cancer care in Egypt. Knowledge about resource use/costs can help in better resource planning to improve care and outcomes efficiently. In this study, we estimated patterns and trends of hospital resource use and costs for children with cancer (n = 8886, aged 0-18 years) treated at Children's Cancer Hospital, Egypt (CCHE), between 2013 and 2017, by ICCC-3 groups, at one and three years post-diagnosis. Read More

View Article and Full-Text PDF
September 2021

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Cell Biol Toxicol 2021 Sep 14. Epub 2021 Sep 14.

Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Piero Maroncelli, 40, 47014, Meldola, FC, Italy.

Doxorubicin (Dox) is one of the most commonly used anthracyclines for the treatment of solid and hematological tumors such as B-/T cell acute lymphoblastic leukemia (ALL). Dox compromises topoisomerase II enzyme functionality, thus inducing structural damages during DNA replication and causes direct damages intercalating into DNA double helix. Eukaryotic cells respond to DNA damages by activating the ATM-CHK2 and/or ATR-CHK1 pathway, whose function is to regulate cell cycle progression, to promote damage repair, and to control apoptosis. Read More

View Article and Full-Text PDF
September 2021

Critical illness in patients with hematologic malignancy: a population-based cohort study.

Intensive Care Med 2021 Sep 14. Epub 2021 Sep 14.

Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada.

Purpose: To describe the modern incidence and predictors of ICU admission for adult patients newly diagnosed with a hematologic malignancy.

Methods: We conducted a population-based cohort study of adults with a new diagnosis of hematologic malignancy (April 1, 2006-March 31, 2017) in Ontario, Canada. We described the baseline demographic, clinical and laboratory predictors of ICU admission and subsequent mortality. Read More

View Article and Full-Text PDF
September 2021

Common maternal infections during pregnancy and childhood leukaemia in the offspring: findings from six international birth cohorts.

Int J Epidemiol 2021 Sep 14. Epub 2021 Sep 14.

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.

Background: Previous epidemiological studies have found positive associations between maternal infections and childhood leukaemia; however, evidence from prospective cohort studies is scarce. We aimed to examine the associations using large-scale prospective data.

Methods: Data were pooled from six population-based birth cohorts in Australia, Denmark, Israel, Norway, the UK and the USA (recruitment 1950s-2000s). Read More

View Article and Full-Text PDF
September 2021

Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey.

Leuk Lymphoma 2021 Sep 14:1-2. Epub 2021 Sep 14.

Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Full-Text PDF
September 2021

OSR1 suppresses acute myeloid leukaemia cell proliferation by inhibiting LGR5-mediated JNK signalling.

Autoimmunity 2021 Sep 14:1-8. Epub 2021 Sep 14.

Department of Clinical Laboratory, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.

Odd-skipped related transcription factor 1 (OSR1) is implicated in various pathophysiologic processes, such as embryonic heart and urogenital formation, and functions as a tumour suppressor in diverse tumours. Regardless, the regulatory role and mechanism of OSR1 in acute myeloid leukaemia are scarce. Firstly, the CD34-positive blasts or the normal blasts were isolated from the plasma samples of acute myeloid leukaemia patients or healthy donors, respectively. Read More

View Article and Full-Text PDF
September 2021

CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab.

Pediatr Blood Cancer 2021 Sep 14:e29323. Epub 2021 Sep 14.

Department of Pediatric Hematology-Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy.

Blinatumomab is a BiTE (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated significant activity in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL); however, a subset of patients relapse. Monitoring expression of cluster of differentiation (CD)19 in relapsed patients is critical to inform sequencing of subsequent therapies. The expression of CD19 in 59 pediatric patients with R/R B-ALL was analyzed on the day of diagnosis of R/R B-ALL and on days 15 and 29 of cycle 1 of blinatumomab. Read More

View Article and Full-Text PDF
September 2021

Reply to: Comment on: Unsatisfactory quality of E. coli asparaginase biogenerics in India-Implications for clinical outcomes in acute lymphoblastic leukaemia.

Pediatr Blood Cancer 2021 Sep 14:e29334. Epub 2021 Sep 14.

Department of Paediatric Haematology and Oncology, Tata Medical Center, Kolkata, India.

View Article and Full-Text PDF
September 2021

Atypical imaging presentation of herpes simplex virus encephalitis in paediatric immunocompromised oncology patients.

J Med Imaging Radiat Oncol 2021 Sep 14. Epub 2021 Sep 14.

Tata Memorial Centre, Mumbai, India.

Introduction: We aim to assess the imaging manifestations of brain involvement in paediatric immunocompromised patients with haematological malignancies on chemotherapy presenting with encephalitis and positive HSV CSF PCR. We also aim to determine whether our findings are similar or different to those described in literature for paediatric patients in general.

Methods: A retrospective study was performed in paediatric ALL/lymphoma patients on chemotherapy, and cases with positive CSF HSV-PCR with at least one head MRI scan were included. Read More

View Article and Full-Text PDF
September 2021

The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.

Nat Commun 2021 Sep 13;12(1):5397. Epub 2021 Sep 13.

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Acute myeloid leukemia (AML) remains incurable, largely due to its resistance to conventional treatments. Here, we find that increased abundance of the ubiquitin ligase RNF5 contributes to AML development and survival. High RNF5 expression in AML patient specimens correlates with poor prognosis. Read More

View Article and Full-Text PDF
September 2021

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-positive AML.

Mol Cancer Ther 2021 Sep 13. Epub 2021 Sep 13.

Pharmaceutical Sciences, The Ohio State University

Acute myeloid leukemia (AML) with a FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy associated with frequent relapse and poor overall survival. The tyrosine kinase inhibitor gilteritinib is approved for the treatment of relapse/refractory AML with FLT3 mutations, yet its mechanism of action is not completely understood. Here, we sought to identify additional therapeutic targets that can be exploited to enhance gilteritinib's anti-leukemic effect. Read More

View Article and Full-Text PDF
September 2021